

PRODUCT INFORMATION




Enzomenib

Item No. 44271

CAS Registry No.: 2412555-70-3
Formal Name: 5-fluoro-2-[[4-[7-[[[(1S,3S,4R)-5-methylene-2-azabicyclo[2.2.2]oct-3-yl]carbonyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-N,N-bis(1-methylethyl)-benzamide

Synonym: DSP-5336
MF: C₃₃H₄₃FN₆O₃
FW: 590.7
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Enzomenib is supplied as a solid. A stock solution may be made by dissolving the enzomenib in the solvent of choice, which should be purged with an inert gas. Enzomenib is slightly soluble (0.1-1 mg/ml) in acetonitrile and DMSO.

Description

Enzomenib is an inhibitor of the protein-protein interaction between menin and mixed-lineage leukemia 1 (MLL1).¹ It binds to menin ($K_d = 6$ nM) and inhibits the menin-MLL1 interaction with an IC_{50} value of 1.4 nM. Enzomenib selectively inhibits the growth of MV4-11, MOLM-13, KOPN-8, and OCI-AML-3 leukemia cells (IC_{50} s = 10, 15, 31, and 15 nM, respectively), which contain MLL rearrangement (MLL-r) or NPM1 mutations, over HL-60, MOLT-4, and Reh leukemia cells (IC_{50} s = >10 μ M for all), which do not have MLL-r or NPM1 mutations. *In vivo*, enzomenib (25 and 50 mg/kg) has antitumor activity in a mouse xenograft model using MV4-11 cells, which express an MLL-AF4 gene fusion.

Reference

1. Eguchi, K., Shimizu, T., Kato, D., *et al.* Preclinical evaluation of a novel orally bioavailable menin-MLL interaction inhibitor, DSP-5336, for the treatment of acute leukemia patients with MLL-rearrangement or NPM1 mutation. *Blood* **138**(Suppl. 1), 3339 (2021).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/03/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM